keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer review

keyword
https://www.readbyqxmd.com/read/28636979/exosomes-in-diagnosis-and-therapy-of-prostate-cancer
#1
REVIEW
Jun Pan, Meng Ding, Kai Xu, Chunhua Yang, Li-Jun Mao
Exosomes are small vesicular bodies released by a variety of cells. Exosomes contain miRNAs, mRNAs and proteins with the potential to regulate signaling pathways in recipient cells. Exosomes deliver nucleic acids and proteins to mediate the communication between cancer cells and stroma cells. In this review, we summarize recent progress in our understanding of the role of exosomes in prostate cancer. The tumorigenesis, metastasis and drug resistance of prostate cancer are associated with the cargos of exosomes such as miRNAs, lncRNAs and proteins...
June 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28636526/does-health-coaching-grow-capacity-in-cancer-survivors-a-systematic-review
#2
Suzette Barakat, Kasey Boehmer, Marwan Abdelrahim, Sangwoo Ahn, Abdulrahman A Al-Khateeb, Neri Álvarez Villalobos, Larry Prokop, Patricia J Erwin, Kirsten Fleming, Valentina Serrano, Gabriela Spencer-Bonilla, Mohammad Hassan Murad
Interventions that grow patient capacity to do the work of health care and life are needed to support the health of cancer survivors. Health coaching may grow capacity. This systematic review of health coaching interventions explored coaching's ability to grow capacity of cancer survivors. The authors included randomized trials or quasi-experimental studies comparing coaching to alternative interventions, and adhered to PRISMA reporting guidelines. Data were analyzed using the Theory of Patient Capacity (BREWS: Capacity is affected by factors that influence ability to reframe Biography ["B"], mobilize or recruit Resources ["R"], interact with the Environment of care ["E"], accomplish Work ["W"]), and function Socially ["S"])...
June 21, 2017: Population Health Management
https://www.readbyqxmd.com/read/28636142/clinical-development-of-immunotherapy-for-prostate-cancer
#3
REVIEW
Masanori Noguchi, Noriko Koga, Tsukasa Igawa, Kyogo Itoh
Prostate cancer is the most common cancer in men, and the second leading cause of cancer-related death in Western countries. Prostate cancer-related death occurs in patients with metastatic castration-resistant prostate cancer. Although several new drugs for castration-resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients...
June 21, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28636139/review-of-hplc-and-lc-ms-ms-assays-for-the-determination-of-various-non-steroidal-anti-androgens-nsaa-used-in-the-treatment-of-prostate-cancer
#4
REVIEW
P S Suresh, Nuggehally R Srinivas, Ramesh Mullangi
Prostate cancer is the most common cancer and one of the leading causes for cancer deaths in men. One of the commonly used approaches to treat metastatic prostate cancer was via first generation non-steroidal anti-androgens (NSAA) namely flutamide, nilutamide, bicalutamide and topilutamide. Most of the prostate cancer patients who are initially responsive develop a most aggressive form of disease called castration-resistant prostate cancer (CRPC). Second generation NSAA receptor antagonists (enzalutamide, apalutamide and darolutamide) are emerging as additional new options to treat CRPC...
June 21, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28633309/tmprss2-erg-gene-fusions-in-prostate-cancer-of-west-african-men-and-a-meta-analysis-of-racial-differences
#5
Cindy Ke Zhou, Denise Young, Edward D Yeboah, Sally B Coburn, Yao Tettey, Richard B Biritwum, Andrew A Adjei, Evelyn Tay, Shelley Niwa, Ann Truelove, Judith Welsh, James E Mensah, Robert N Hoover, Isabell A Sesterhenn, Ann W Hsing, Shiv Srivastava, Michael B Cook
The prevalence of TMPRSS2-ERG fusions in prostate cancer varies by race. However, such somatic aberration and its association with prognostic factors have neither been studied in a West African population nor been systematically reviewed in the context of racial differences. We used immunohistochemistry to assess ERG expression as the established surrogate of ERG fusion genes among 262 prostate cancer biopsies from the Ghana Prostate Study. Poisson regression with robust variance estimation provided prevalence ratios and 95% confidence intervals of ERG expression in relation to patients' characteristics...
June 12, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28631917/-contemporary-concept-of-the-diagnosis-of-prostate-cancer
#6
Yu Yu Vinnik, A V Andreichikov, N Yu Klimov
This review summarizes current evidence of the etiology and diagnosis of prostate cancer. As before, a comprehensive urological examination remains the main method of diagnosing the disease. However, the invasive nature of the multicore prostate biopsy, its high cost and the need for specially trained personnel prompts to seek more state-of-the-art and non-invasive methods for diagnosing prostate cancer. The further research in this direction seems promising.
June 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28629566/pi-rads-version-2-preoperative-role-in-the-detection-of-normal-sized-pelvic-lymph-node-metastasis-in-prostate-cancer
#7
Sung Yoon Park, Su-Jin Shin, Dae Chul Jung, Nam Hoon Cho, Young Deuk Choi, Koon Ho Rha, Sung Joon Hong, Young Taik Oh
OBJECTIVES: To analyze whether Prostate Imaging Reporting and Data System (PI-RADSv2) scores are associated with a risk of normal-sized pelvic lymph node metastasis (PLNM) in prostate cancer (PCa). MATERIALS AND METHODS: A consecutive series of 221 patients who underwent magnetic resonance imaging and radical prostatectomy with pelvic lymph node dissection (PLND) for PCa were retrospectively analyzed under the approval of institutional review board in our institution...
June 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28627814/prognostic-role-of-circulating-soluble-upar-in-various-cancers-a-systematic-review-and-meta-analysis
#8
REVIEW
K L Liu, J H Fan, Jing Wu
BACKGROUND: Soluble uPAR (suPAR) is a soluble fraction of uPAR which is an important cell surface receptor. Recent evidence suggests that circulating suPAR levels are elevated in multiple malignancies and associated with prognosis of patients, although the results are not consistent. This study aimed to analyze the effect of suPAR on the prognosis in various carcinomas through a systematic review and meta-analysis. METHODS: Eligible studies were searched in PubMed and EMBASE...
May 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28624514/bromodomain-containing-proteins-in-prostate-cancer
#9
REVIEW
Alfonso Urbanucci, Ian G Mills
Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chromatin-modifying enzymes or factors that bind to epigenetic modifications to chromatin...
June 14, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28623628/does-patient-preference-measurement-in-decision-aids-improve-decisional-conflict-a-randomized-trial-in-men-with-prostate-cancer
#10
Joseph D Shirk, Catherine M Crespi, Josemanuel D Saucedo, Sylvia Lambrechts, Ely Dahan, Robert Kaplan, Christopher Saigal
BACKGROUND: Shared decision making (SDM) has been advocated as an approach to medical decision making that can improve decisional quality. Decision aids are tools that facilitate SDM in the context of limited physician time; however, many decision aids do not incorporate preference measurement. OBJECTIVES: We aim to understand whether adding preference measurement to a standard patient educational intervention improves decisional quality and is feasible in a busy clinical setting...
June 16, 2017: Patient
https://www.readbyqxmd.com/read/28623436/high-dose-rate-brachytherapy-as-salvage-modality-for-locally-recurrent-prostate-cancer-after-definitive-radiotherapy-a%C3%A2-systematic-review
#11
REVIEW
Georgios Chatzikonstantinou, Nikolaos Zamboglou, Claus Rödel, Eleni Zoga, Iosif Strouthos, Saeed Ahmed Butt, Nikolaos Tselis
PURPOSE: To review the current status of interstitial high-dose-rate brachytherapy as a salvage modality (sHDR BRT) for locally recurrent prostate cancer after definitive radiotherapy (RT). MATERIALS AND METHODS: A literature search was performed in PubMed using "high-dose-rate, brachytherapy, prostate cancer, salvage" as search terms. In all, 51 search results published between 2000 and 2016 were identified. Data tables were generated and summary descriptions created...
June 16, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28620703/epidemiology-and-biology-of-physical-activity-and-cancer-recurrence
#12
REVIEW
Christine M Friedenreich, Eileen Shaw, Heather K Neilson, Darren R Brenner
Physical activity is emerging from epidemiologic research as a lifestyle factor that may improve survival from colorectal, breast, and prostate cancers. However, there is considerably less evidence relating physical activity to cancer recurrence and the biologic mechanisms underlying this association remain unclear. Cancer patients are surviving longer than ever before, and fear of cancer recurrence is an important concern. Herein, we provide an overview of the current epidemiologic evidence relating physical activity to cancer recurrence...
June 15, 2017: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/28620691/biomarkers-for-the-management-of-castration-resistant-prostate-cancer-we-are-not-there-yet
#13
Daniel P Petrylak, E David Crawford
In recent years, there has been a marked increase in the number of approved therapies that increase survival of patients with castration-resistant prostate cancer. Current treatment guidelines provide therapeutic management recommendations, but these are primarily based on clinical factors such as performance status or site of metastasis (bone vs. visceral), and not on underlying molecular or cellular features of disease that may predict response. The ability to tailor treatment based on molecular or cellular features of disease could potentially reduce the occurrence of unnecessary side effects and ineffective treatments, and thereby reduce both direct and indirect medical costs...
June 16, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28614882/-review-on-quality-of-life-in-crpc-patients
#14
Kurt Miller
Health-related quality of life (HRQoL) deteriorates rapidly in patients with advanced-stage cancer, with patients seriously disturbed by fatigue, sleep disorders, bone pain, constipation and other disease related symptoms. As treatment and prognosis continues to improve, reducing symptoms and improving quality of life with minimum of toxicities have become important therapeutic goals. The effectiveness of abiraterone acetate and enzalutamide in both prolonging life and improving quality of life in asymptomatic or mildly symptomatic patients with metastatic castrations-resistant prostate cancer (mCRPC) has been clinically proven...
May 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28614217/psa-declines-and-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-enzalutamide-a-retrospective-case-report-study
#15
Davide Bosso, Martina Pagliuca, Guru Sonpavde, Gregory Pond, Giuseppe Lucarelli, Sabrina Rossetti, Gaetano Facchini, Sarah Scagliarini, Giacomo Cartenì, Bruno Daniele, Franco Morelli, Matteo Ferro, Livio Puglia, Michela Izzo, Vittorino Montanaro, Teresa Bellelli, Francesca Vitrone, Sabino De Placido, Carlo Buonerba, Giuseppe Di Lorenzo
RATIONALE: PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses. PATIENT CONCERNS: However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined. DIAGNOSES AND INTERVENTATIONS: Medical records of patients with documented mCRPC treated with enzalutamide between September 2011 and August 2016 were reviewed at multiple participating centers and assessed for overall survival (OS), PSA variations, and other variables of interest...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28614086/the-present-and-future-of-prostate-cancer-histopathology
#16
Jesse K McKenney
PURPOSE OF REVIEW: The present review describes recent changes in the histologic grading of prostatic adenocarcinoma and emerging data suggesting areas for further grade optimization. RECENT FINDINGS: The grading of prostatic adenocarcinoma has evolved over time, and optimization for active surveillance management has been one major driving force. Recent changes include adoption of the Grade Group system, which stratifies patients into one of five prognostic groups...
June 12, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28613200/clinical-significance-of-18-f-fluorodeoxyglucose-avid-prostate-gland-incidentalomas-on-positron-emission-tomography-computed-tomography
#17
William Makis, Anthony Ciarallo
OBJECTIVE: The aim of this study was to evaluate the clinical significance of incidental focal uptake of (18)F-fluorodeoxyglucose ((18)F-FDG) on positron emission tomography/computed tomography (PET/CT) in the prostate glands of cancer patients. METHODS: A retrospective review of 3122 consecutive male patients who underwent (18)F-FDG PET/CT studies with an oncologic indication, over the course of four years, was performed. Studies with incidental (18)F-FDG uptake in the prostate gland were further analyzed...
June 1, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28611276/vitamin-k-and-its-analogs-potential-avenues-for-prostate-cancer-management
#18
REVIEW
Subramanyam Dasari, Syed M Ali, Guoxing Zheng, Aoshuang Chen, Venkata Satish Dontaraju, Maarten C Bosland, Andre Kajdacsy-Balla, Gnanasekar Munirathinam
Epidemiological studies have demonstrated a relationship between cancer incidence and dietary habits. Especially intake of certain essential nutrients like vitamins has been shown to be beneficial in experimental studies and some clinical trials. Vitamin K (VK) is an essential nutrient involved in the blood clotting cascade, and there are considerable experimental data demonstrating its potential anticancer activity in several cancer types including prostate cancer. Previous in vitro and in vivo studies have focused mainly on anti-oxidative effects as the underlying anticancer mechanism of VK...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28610779/survival-and-complications-following-surgery-and-radiation-for-localized-prostate-cancer-an-international-collaborative-review
#19
REVIEW
Christopher J D Wallis, Adam Glaser, Jim C Hu, Hartwig Huland, Nathan Lawrentschuk, Daniel Moon, Declan G Murphy, Paul L Nguyen, Matthew J Resnick, Robert K Nam
BACKGROUND: Evaluation of treatment options for localized prostate cancer (PCa) remains among the highest priorities for comparative effectiveness research. Surgery and radiotherapy (RT) are the two interventions most commonly used. OBJECTIVE: To provide a critical narrative review of evidence of the comparative effectiveness and harms of surgery and RT in the treatment of localized PCa. EVIDENCE ACQUISITION: A collaborative critical narrative review of the literature was conducted...
June 10, 2017: European Urology
https://www.readbyqxmd.com/read/28610671/pulmonary-manifestations-of-urothelial-carcinoma-of-the-bladder
#20
REVIEW
Abhinav Agrawal, Sonu Sahni, Abhinav K Vulisha, Rammohan Gumpeni, Rakesh Shah, Arunabh Talwar
Urothelial carcinoma (Transitional cell carcinoma) of the bladder is the pre-dominant histological type of bladder cancer in the United States and Europe. Patients with bladder cancer usually present with painless hematuria. The diagnosis is often delayed, as the symptoms are similar to various other benign conditions such as urinary tract infection, prostatitis or renal calculi. In some patients, the metastatic lesions will cause the initial presenting symptoms. We conducted a MedLine/PubMED search identifying all relevant articles with "pulmonary manifestations", "urothelial bladder cancer", "manifestations of bladder cancer" or a combination of these terms in the title...
July 2017: Respiratory Medicine
keyword
keyword
111539
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"